DK3935068T3 - Abirateron-prodrugs - Google Patents
Abirateron-prodrugs Download PDFInfo
- Publication number
- DK3935068T3 DK3935068T3 DK20717363.4T DK20717363T DK3935068T3 DK 3935068 T3 DK3935068 T3 DK 3935068T3 DK 20717363 T DK20717363 T DK 20717363T DK 3935068 T3 DK3935068 T3 DK 3935068T3
- Authority
- DK
- Denmark
- Prior art keywords
- abirateron
- product drugs
- drugs
- product
- abirateron product
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962814568P | 2019-03-06 | 2019-03-06 | |
| US201962849259P | 2019-05-17 | 2019-05-17 | |
| PCT/US2020/020915 WO2020180942A1 (en) | 2019-03-06 | 2020-03-04 | Abiraterone prodrugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3935068T3 true DK3935068T3 (da) | 2023-12-04 |
Family
ID=70190090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20717363.4T DK3935068T3 (da) | 2019-03-06 | 2020-03-04 | Abirateron-prodrugs |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10792292B2 (da) |
| EP (2) | EP3935068B1 (da) |
| JP (1) | JP2022523819A (da) |
| KR (1) | KR20210136072A (da) |
| CN (1) | CN114026106A (da) |
| AU (1) | AU2020232706A1 (da) |
| BR (1) | BR112021017377A2 (da) |
| CA (1) | CA3131034A1 (da) |
| DK (1) | DK3935068T3 (da) |
| ES (1) | ES2964818T3 (da) |
| IL (1) | IL286048A (da) |
| MX (1) | MX2021010553A (da) |
| PL (1) | PL3935068T3 (da) |
| WO (1) | WO2020180942A1 (da) |
| ZA (1) | ZA202107278B (da) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114026106A (zh) * | 2019-03-06 | 2022-02-08 | 普洛拉治疗公司 | 阿比特龙前药 |
| US20210202095A1 (en) * | 2019-12-26 | 2021-07-01 | Cerner Innovation, Inc. | Decision support application for pcos |
| EP4208171A1 (en) * | 2020-09-02 | 2023-07-12 | Propella Therapeutics, Inc. | Abiraterone prodrugs |
| CN113929727A (zh) * | 2020-09-28 | 2022-01-14 | 南京易腾药物研究院有限公司 | 阿比特龙酯类衍生物及其制备方法和应用 |
| CA3207282A1 (en) | 2021-02-15 | 2022-08-18 | Matthew J. Sharp | Abiraterone prodrugs |
| CN113061154B (zh) * | 2021-03-25 | 2022-07-08 | 天津海润家和创新医药研究有限责任公司 | 新型注射用阿比特龙衍生物的制备方法和用途 |
| CN113527401A (zh) * | 2021-08-26 | 2021-10-22 | 雷昊言 | 一种阿比特龙前体化合物及其制备方法和应用 |
| CN118215466A (zh) | 2021-09-08 | 2024-06-18 | 普洛佩拉治疗公司 | 口服阿比特龙制剂 |
| IL315174A (en) | 2022-03-01 | 2024-10-01 | Propella Therapeutics Inc | Abiraterone decanoate drug metrics and treatment use |
| WO2024107928A1 (en) | 2022-11-16 | 2024-05-23 | Propella Therapeutics, Inc. | Abiraterone decanoate composition and use in therapy |
| CN116046950A (zh) * | 2023-01-18 | 2023-05-02 | 河北省药品医疗器械检验研究院(河北省化妆品检验研究中心) | 一种检测醋酸阿比特龙中5种杂质的方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5604213A (en) | 1992-03-31 | 1997-02-18 | British Technology Group Limited | 17-substituted steroids useful in cancer treatment |
| GB0418900D0 (en) | 2004-08-24 | 2004-09-29 | Btg Int Ltd | Novel salt forms |
| US20080051380A1 (en) * | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
| US20090124587A1 (en) | 2007-07-12 | 2009-05-14 | Auerbach Alan H | METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS |
| EP3023433A1 (en) | 2009-02-05 | 2016-05-25 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens |
| EP2506855A4 (en) | 2009-11-30 | 2014-07-30 | Harbor Biosciences Inc | ANTICARCINOMA COMPOUNDS AND SCREENING METHODS |
| ES2590753T3 (es) | 2011-10-10 | 2016-11-23 | Zach System | Proceso para la preparación de esteroides 17-sustituidos |
| US20140079636A1 (en) | 2012-04-16 | 2014-03-20 | Dinesh U. Chimmanamada | Targeted therapeutics |
| EP2841444A4 (en) | 2012-04-23 | 2015-11-04 | Alphora Res Inc | PROCESS FOR PREPARING 17-SUBSTITUTED STEROIDS |
| WO2014009434A1 (en) | 2012-07-11 | 2014-01-16 | Sandoz Ag | Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate |
| US20140011992A1 (en) | 2012-12-20 | 2014-01-09 | Crystal Pharma, S.A.U. | Synthesis of abiraterone and related compounds |
| EP2945960A2 (en) * | 2013-01-18 | 2015-11-25 | Cortendo AB (publ) | Abiraterone and analogs thereof for the treatment of diseases associated with cortisol overproduction |
| US20140287039A1 (en) | 2013-03-15 | 2014-09-25 | Iceutica Inc. | Abiraterone Acetate Formulation |
| US20150246060A1 (en) | 2013-03-15 | 2015-09-03 | Iceutica Inc. | Abiraterone Acetate Formulation and Methods of Use |
| WO2015038649A1 (en) | 2013-09-10 | 2015-03-19 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
| US20150157646A1 (en) | 2013-09-27 | 2015-06-11 | Iceutica Inc. | Abiraterone Steroid Formulation |
| MA39481A (fr) | 2014-03-03 | 2015-09-11 | Synta Pharmaceuticals Corp | Thérapies ciblées |
| EP3131586A4 (en) | 2014-03-18 | 2017-10-25 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics |
| CN104017045B (zh) * | 2014-06-23 | 2016-01-13 | 广州艾格生物科技有限公司 | 甾体cyp17抑制剂的新型药物前体及其应用、制备方法 |
| US9937259B2 (en) * | 2014-06-27 | 2018-04-10 | Zhuhai Beihai Biotech Co., Ltd. | Abiraterone derivatives and non-covalent complexes with albumin |
| BR112017003219A2 (pt) | 2014-09-18 | 2017-11-28 | Iceutica Inc | formulação de acetato de abiraterona e métodos de uso |
| CN104356191A (zh) | 2014-09-29 | 2015-02-18 | 上海延安药业（湖北）有限公司 | 阿比特龙单琥珀酸酯及其制备方法 |
| CN105646637B (zh) | 2014-11-28 | 2018-12-14 | 四川海思科制药有限公司 | 一种阿比特龙衍生物及其制备方法和医药用途 |
| CN104447394B (zh) * | 2014-12-17 | 2017-01-18 | 成都傲飞生物化学品有限责任公司 | 一种乌苯美司的新型合成工艺 |
| CN104710499A (zh) | 2015-02-15 | 2015-06-17 | 重庆医药工业研究院有限责任公司 | 一种丙酸阿比特龙的晶型及其制备方法 |
| CA3008909C (en) * | 2015-12-23 | 2023-10-03 | The University Of British Columbia | Lipid-linked prodrugs |
| JP6842474B2 (ja) | 2016-02-02 | 2021-03-17 | 深▲セン▼市塔吉瑞生物医▲薬▼有限公司Ｓｈｅｎｚｈｅｎ ＴａｒｇｅｔＲｘ，Ｉｎｃ． | ステロイド系化合物、当該化合物を含む組成物及びその使用 |
| WO2018071544A1 (en) | 2016-10-11 | 2018-04-19 | Zhuhai Beihai Biotech Co., Ltd. | Abiraterone derivative and formulations thereof |
| CN106977577A (zh) | 2017-04-21 | 2017-07-25 | 湖南师范大学 | 两类阿比特龙衍生物的合成 |
| CN114026106A (zh) * | 2019-03-06 | 2022-02-08 | 普洛拉治疗公司 | 阿比特龙前药 |
-
2020
- 2020-03-04 CN CN202080032112.9A patent/CN114026106A/zh active Pending
- 2020-03-04 DK DK20717363.4T patent/DK3935068T3/da active
- 2020-03-04 JP JP2021552742A patent/JP2022523819A/ja active Pending
- 2020-03-04 MX MX2021010553A patent/MX2021010553A/es unknown
- 2020-03-04 CA CA3131034A patent/CA3131034A1/en active Pending
- 2020-03-04 ES ES20717363T patent/ES2964818T3/es active Active
- 2020-03-04 AU AU2020232706A patent/AU2020232706A1/en active Pending
- 2020-03-04 US US16/808,912 patent/US10792292B2/en active Active
- 2020-03-04 EP EP20717363.4A patent/EP3935068B1/en active Active
- 2020-03-04 EP EP23188119.4A patent/EP4286006A3/en active Pending
- 2020-03-04 PL PL20717363.4T patent/PL3935068T3/pl unknown
- 2020-03-04 KR KR1020217032021A patent/KR20210136072A/ko unknown
- 2020-03-04 BR BR112021017377A patent/BR112021017377A2/pt unknown
- 2020-03-04 WO PCT/US2020/020915 patent/WO2020180942A1/en unknown
- 2020-08-10 US US16/989,304 patent/US11559534B2/en active Active
-
2021
- 2021-09-01 IL IL286048A patent/IL286048A/en unknown
- 2021-09-28 ZA ZA2021/07278A patent/ZA202107278B/en unknown
-
2023
- 2023-01-19 US US18/098,798 patent/US20230233582A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20200368255A1 (en) | 2020-11-26 |
| EP3935068A1 (en) | 2022-01-12 |
| ES2964818T3 (es) | 2024-04-09 |
| US20200281945A1 (en) | 2020-09-10 |
| CA3131034A1 (en) | 2020-09-10 |
| CN114026106A (zh) | 2022-02-08 |
| JP2022523819A (ja) | 2022-04-26 |
| KR20210136072A (ko) | 2021-11-16 |
| EP4286006A2 (en) | 2023-12-06 |
| US10792292B2 (en) | 2020-10-06 |
| AU2020232706A1 (en) | 2021-09-16 |
| BR112021017377A2 (pt) | 2021-11-16 |
| EP3935068B1 (en) | 2023-09-06 |
| EP4286006A3 (en) | 2024-03-20 |
| MX2021010553A (es) | 2021-12-15 |
| PL3935068T3 (pl) | 2024-02-26 |
| ZA202107278B (en) | 2023-06-28 |
| IL286048A (en) | 2021-10-31 |
| US11559534B2 (en) | 2023-01-24 |
| WO2020180942A1 (en) | 2020-09-10 |
| US20230233582A1 (en) | 2023-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3935068T3 (da) | Abirateron-prodrugs | |
| GB2569961B (en) | Pharmaceutical | |
| GB2572126B (en) | Pharmaceutical | |
| GB2572125B (en) | Pharmaceutical | |
| DK3529240T3 (da) | Farmaceutiske forbindelser | |
| DK3634377T3 (da) | Farmaceutisk formulering | |
| DK3583943T3 (da) | Farmaceutisk sammensætning | |
| DK3601277T3 (da) | Farmaceutisk formulering | |
| MA46642A (fr) | Promédicaments d'inhibiteurs de la kallicréine | |
| DK3996688T3 (da) | Farmaceutisk præparat | |
| DK3288967T3 (da) | Farmaceutisk forbindelse | |
| DK3908321T3 (da) | Farmaceutisk sammensætning | |
| DK3728220T3 (da) | Farmaceutiske forbindelser | |
| UA41530S (uk) | Ювелірний виріб | |
| UA39739S (uk) | Шоколадний виріб | |
| UA40741S (uk) | Кондитерський виріб | |
| UA40968S (uk) | Кондитерський виріб | |
| UA40877S (uk) | Кондитерський виріб | |
| UA40169S (uk) | Кондитерський виріб | |
| IT201900023238A1 (it) | Prodotto alimentare | |
| UA39361S (uk) | Кондитерський виріб | |
| UA39218S (uk) | Кондитерський виріб | |
| UY4585S (es) | Comprimidos farmacéuticos | |
| CL2017002185S1 (es) | Tableta farmacéutica | |
| UA37974S (uk) | Кондитерський виріб |